Literature DB >> 26347318

A splicing-regulatory polymorphism in DRD2 disrupts ZRANB2 binding, impairs cognitive functioning and increases risk for schizophrenia in six Han Chinese samples.

O S Cohen1, T W Weickert2,3,4, J L Hess1, L M Paish1, S Y McCoy1, D A Rothmond3, C Galletly5,6, D Liu6, D D Weinberg3, X-F Huang6,7, Q Xu8, Y Shen8, D Zhang9, W Yue9, J Yan9, L Wang9, T Lu9, L He10, Y Shi10, M Xu10, R Che10, W Tang10, C-H Chen11, W-H Chang11, H-G Hwu12,13,14, C-M Liu12, Y-L Liu12, C-C Wen12, C S-J Fann15, C-C Chang15, T Kanazawa16, F A Middleton17, T M Duncan18, S V Faraone17,19, C S Weickert2,3,4, M T Tsuang20,21,22, S J Glatt1,17,19.   

Abstract

The rs1076560 polymorphism of DRD2 (encoding dopamine receptor D2) is associated with alternative splicing and cognitive functioning; however, a mechanistic relationship to schizophrenia has not been shown. Here, we demonstrate that rs1076560(T) imparts a small but reliable risk for schizophrenia in a sample of 616 affected families and five independent replication samples totaling 4017 affected and 4704 unaffected individuals (odds ratio=1.1; P=0.004). rs1076560(T) was associated with impaired verbal fluency and comprehension in schizophrenia but improved performance among healthy comparison subjects. rs1076560(T) also associated with lower D2 short isoform expression in postmortem brain. rs1076560(T) disrupted a binding site for the splicing factor ZRANB2, diminished binding affinity between DRD2 pre-mRNA and ZRANB2 and abolished the ability of ZRANB2 to modulate short:long isoform-expression ratios of DRD2 minigenes in cell culture. Collectively, this work implicates rs1076560(T) as one possible risk factor for schizophrenia in the Han Chinese population, and suggests molecular mechanisms by which it may exert such influence.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26347318     DOI: 10.1038/mp.2015.137

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  29 in total

1.  PBAT: tools for family-based association studies.

Authors:  Christoph Lange; Dawn DeMeo; Edwin K Silverman; Scott T Weiss; Nan M Laird
Journal:  Am J Hum Genet       Date:  2004-02       Impact factor: 11.025

Review 2.  Dopamine D2 receptors as treatment targets in schizophrenia.

Authors:  Philip Seeman
Journal:  Clin Schizophr Relat Psychoses       Date:  2010-04

3.  D2 receptor genotype and striatal dopamine signaling predict motor cortical activity and behavior in humans.

Authors:  Leonardo Fazio; Giuseppe Blasi; Paolo Taurisano; Apostolos Papazacharias; Raffaella Romano; Barbara Gelao; Gianluca Ursini; Tiziana Quarto; Luciana Lo Bianco; Annabella Di Giorgio; Marina Mancini; Teresa Popolizio; Giuseppe Rubini; Alessandro Bertolino
Journal:  Neuroimage       Date:  2010-11-16       Impact factor: 6.556

4.  Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database.

Authors:  Nicole C Allen; Sachin Bagade; Matthew B McQueen; John P A Ioannidis; Fotini K Kavvoura; Muin J Khoury; Rudolph E Tanzi; Lars Bertram
Journal:  Nat Genet       Date:  2008-07       Impact factor: 38.330

5.  Genetically determined measures of striatal D2 signaling predict prefrontal activity during working memory performance.

Authors:  Alessandro Bertolino; Paolo Taurisano; Nicola Marco Pisciotta; Giuseppe Blasi; Leonardo Fazio; Raffaella Romano; Barbara Gelao; Luciana Lo Bianco; Madia Lozupone; Annabella Di Giorgio; Grazia Caforio; Fabio Sambataro; Artor Niccoli-Asabella; Audrey Papp; Gianluca Ursini; Lorenzo Sinibaldi; Teresa Popolizio; Wolfgang Sadee; Giuseppe Rubini
Journal:  PLoS One       Date:  2010-02-22       Impact factor: 3.240

6.  Family-based association testing strongly implicates DRD2 as a risk gene for schizophrenia in Han Chinese from Taiwan.

Authors:  S J Glatt; S V Faraone; J A Lasky-Su; T Kanazawa; H-G Hwu; M T Tsuang
Journal:  Mol Psychiatry       Date:  2008-03-11       Impact factor: 15.992

7.  Chronic haloperidol promotes corticostriatal long-term potentiation by targeting dopamine D2L receptors.

Authors:  Diego Centonze; Alessandro Usiello; Cinzia Costa; Barbara Picconi; Eric Erbs; Giorgio Bernardi; Emiliana Borrelli; Paolo Calabresi
Journal:  J Neurosci       Date:  2004-09-22       Impact factor: 6.167

8.  Common polymorphisms in dopamine-related genes combine to produce a 'schizophrenia-like' prefrontal hypoactivity.

Authors:  A Vercammen; C S Weickert; A J Skilleter; R Lenroot; P R Schofield; T W Weickert
Journal:  Transl Psychiatry       Date:  2014-02-04       Impact factor: 6.222

9.  DRD2/CHRNA5 interaction on prefrontal biology and physiology during working memory.

Authors:  Annabella Di Giorgio; Ryan M Smith; Leonardo Fazio; Enrico D'Ambrosio; Barbara Gelao; Aldo Tomasicchio; Pierluigi Selvaggi; Paolo Taurisano; Tiziana Quarto; Rita Masellis; Antonio Rampino; Grazia Caforio; Teresa Popolizio; Giuseppe Blasi; Wolfgang Sadee; Alessandro Bertolino
Journal:  PLoS One       Date:  2014-05-12       Impact factor: 3.240

10.  Biological insights from 108 schizophrenia-associated genetic loci.

Authors: 
Journal:  Nature       Date:  2014-07-22       Impact factor: 49.962

View more
  12 in total

1.  Arsenite Exposure Displaces Zinc from ZRANB2 Leading to Altered Splicing.

Authors:  Mayukh Banerjee; Ana P Ferragut Cardoso; Angeliki Lykoudi; Daniel W Wilkey; Jianmin Pan; Walter H Watson; Nichola C Garbett; Shesh N Rai; Michael L Merchant; J Christopher States
Journal:  Chem Res Toxicol       Date:  2020-04-27       Impact factor: 3.739

Review 2.  Defective control of pre-messenger RNA splicing in human disease.

Authors:  Benoit Chabot; Lulzim Shkreta
Journal:  J Cell Biol       Date:  2016-01-04       Impact factor: 10.539

3.  Transcriptomic Analysis Shows Decreased Cortical Expression of NR4A1, NR4A2 and RXRB in Schizophrenia and Provides Evidence for Nuclear Receptor Dysregulation.

Authors:  Susan M Corley; Shan-Yuan Tsai; Marc R Wilkins; Cynthia Shannon Weickert
Journal:  PLoS One       Date:  2016-12-16       Impact factor: 3.240

4.  Genome-Wide Supported Risk Variants in MIR137, CACNA1C, CSMD1, DRD2, and GRM3 Contribute to Schizophrenia Susceptibility in Pakistani Population.

Authors:  Ambrin Fatima; Muhammad Farooq; Uzma Abdullah; Muhammad Tariq; Tanveer Mustafa; Muhammad Iqbal; Niels Tommerup; Shahid Mahmood Baig
Journal:  Psychiatry Investig       Date:  2017-09-11       Impact factor: 2.505

Review 5.  Progress in genome-wide association studies of schizophrenia in Han Chinese populations.

Authors:  Weihua Yue; Xin Yu; Dai Zhang
Journal:  NPJ Schizophr       Date:  2017-08-10

6.  Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain.

Authors:  T D Purves-Tyson; S J Owens; D A Rothmond; G M Halliday; K L Double; J Stevens; T McCrossin; C Shannon Weickert
Journal:  Transl Psychiatry       Date:  2017-01-17       Impact factor: 6.222

Review 7.  Molecular mechanisms underlying noncoding risk variations in psychiatric genetic studies.

Authors:  X Xiao; H Chang; M Li
Journal:  Mol Psychiatry       Date:  2017-01-03       Impact factor: 15.992

8.  The transcript expression levels of HNRNPM, HNRNPA0 and AKAP17A splicing factors may be predictively associated with ageing phenotypes in human peripheral blood.

Authors:  Benjamin P Lee; Luke C Pilling; Stefania Bandinelli; Luigi Ferrucci; David Melzer; Lorna W Harries
Journal:  Biogerontology       Date:  2019-07-10       Impact factor: 4.277

Review 9.  An alternative splicing hypothesis for neuropathology of schizophrenia: evidence from studies on historical candidate genes and multi-omics data.

Authors:  Chu-Yi Zhang; Xiao Xiao; Zhuohua Zhang; Zhonghua Hu; Ming Li
Journal:  Mol Psychiatry       Date:  2021-03-08       Impact factor: 15.992

10.  Identification of genetic elements in metabolism by high-throughput mouse phenotyping.

Authors:  Jan Rozman; Birgit Rathkolb; Manuela A Oestereicher; Christine Schütt; Aakash Chavan Ravindranath; Stefanie Leuchtenberger; Sapna Sharma; Martin Kistler; Monja Willershäuser; Robert Brommage; Terrence F Meehan; Jeremy Mason; Hamed Haselimashhadi; Tertius Hough; Ann-Marie Mallon; Sara Wells; Luis Santos; Christopher J Lelliott; Jacqueline K White; Tania Sorg; Marie-France Champy; Lynette R Bower; Corey L Reynolds; Ann M Flenniken; Stephen A Murray; Lauryl M J Nutter; Karen L Svenson; David West; Glauco P Tocchini-Valentini; Arthur L Beaudet; Fatima Bosch; Robert B Braun; Michael S Dobbie; Xiang Gao; Yann Herault; Ala Moshiri; Bret A Moore; K C Kent Lloyd; Colin McKerlie; Hiroshi Masuya; Nobuhiko Tanaka; Paul Flicek; Helen E Parkinson; Radislav Sedlacek; Je Kyung Seong; Chi-Kuang Leo Wang; Mark Moore; Steve D Brown; Matthias H Tschöp; Wolfgang Wurst; Martin Klingenspor; Eckhard Wolf; Johannes Beckers; Fausto Machicao; Andreas Peter; Harald Staiger; Hans-Ulrich Häring; Harald Grallert; Monica Campillos; Holger Maier; Helmut Fuchs; Valerie Gailus-Durner; Thomas Werner; Martin Hrabe de Angelis
Journal:  Nat Commun       Date:  2018-01-18       Impact factor: 17.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.